is being presented by Brian R. Garrison, Attorney, with Baker & Daniels LLP and airs on Tuesday, November 22nd, 2011. For more details or to register, please visit our site at www.fxconferences.com
The Fair Labor Standards Act has become the employment law of choice for many plaintiffs' lawyers, and wage and hour class actions have become the lawsuit du jour for them. Hundreds of these class actions have been filed over the last few years. Wage and hour issues can lead to huge liability and affect employers of all sizes in all industries. This presentation looks at the pay practices and policies that are fueling the flood of class actions. Our speaker discusses common employee classification mistakes and how to properly determine rate of pay. The presentation also reviews the steps you can take to avoid litigation stemming from wage & hour issues, and how to self-audit to ensure compliance and identify potential problems.
Showing posts with label Baker and Daniels LLP. Show all posts
Showing posts with label Baker and Daniels LLP. Show all posts
Wednesday, November 9, 2011
Tuesday, August 23, 2011
Finding the Optimal Regulatory Pathway for Your Combination Product
is being presented by Suzanne O'Shea, Of Counsel, with Baker & Daniels, LLP and airs on Thursday, September 15th, 2011. For more details, or to register please visit our site at www.fxconferences.com
Some view combination products as double the burden, but they also represent an opportunity for creativity and flexibility. And within the complexities of combination products, it is still possible to tailor a regulatory pathway that best meets your specific needs.
This audio conference presentation discusses marketing applications, how many are required and how many would best serve your needs. It also looks at whether the device component of a drug – device combination product can serve as a barrier to generic drug market entry. Our speaker also addresses the issue of cross labeling -- what is it? Is it still a possibility? The presentation explores the flurry of recent guidance documents on companion diagnostics, chemical action, and classifying products as drugs or devices. Do they help or hinder? The presentation provides attendees with a solid understanding of these topics, the possibilities arising from combination product innovations, and the current regulatory environment.
Some view combination products as double the burden, but they also represent an opportunity for creativity and flexibility. And within the complexities of combination products, it is still possible to tailor a regulatory pathway that best meets your specific needs.
This audio conference presentation discusses marketing applications, how many are required and how many would best serve your needs. It also looks at whether the device component of a drug – device combination product can serve as a barrier to generic drug market entry. Our speaker also addresses the issue of cross labeling -- what is it? Is it still a possibility? The presentation explores the flurry of recent guidance documents on companion diagnostics, chemical action, and classifying products as drugs or devices. Do they help or hinder? The presentation provides attendees with a solid understanding of these topics, the possibilities arising from combination product innovations, and the current regulatory environment.
Subscribe to:
Posts (Atom)